Novel function of complement C3d as an autologous helper T-cell target

Immunology and Cell Biology

Volumn 86, Issue 3, 2008, Pages 221-225

  Knopf, Paul M ^a   Rivera, Daniel S ^b   Hai, Si Han ^b   McMurry, Julie ^b   Martin, William ^b   De Groot, Anne S ^b,c  

^a BROWN UNIVERSITY   (United States)

^b EpiVax Inc   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

C3; C3d; Complement; Epitope; Helper T cell; Vaccine

Indexed keywords

CD19 ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C3D RECEPTOR; EPITOPE; GAMMA INTERFERON;

AMINO ACID SEQUENCE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; EPITOPE MAPPING; HAPLOTYPE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PROTEIN FUNCTION; SCORING SYSTEM; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

AUTOIMMUNITY; COMPLEMENT C3D; EPITOPES, T-LYMPHOCYTE; HLA-DR ANTIGENS; HUMANS; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; MOLECULAR MIMICRY; PROTEIN BINDING; RECEPTORS, COMPLEMENT 3D; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER;

BACTERIA (MICROORGANISMS);

EID: 41149101949     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/sj.icb.7100147     Document Type: Article

References (25)

1. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science 1996; 271: 348-350.
2. Haas KM, Toapanta FR, Oliver JA, Poe JC, Weis JH, Karp DR et al. Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. J Immunol 2004; 172: 5833-5837.
3. Bower JF, Ross TM. A minimum CR2 binding domain of C3d enhances immunity following vaccination. Adv Exp Med Biol 2006; 586: 249-264.
4. Jakobsen H, Jonsdottir I. Muscosal vaccination against encapsulated bacteria - new potentials for conjugate vaccines? Scand J Immunol 2003; 58: 119-128.
5. Test ST, Mitsuyoshi J, Connolly CC, Lucas AH. Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infect Immun 2001; 69: 3031-3040.
6. De Groot AS, Goldberg M, Moise L, Martin W. Evolutionary deimmunization: an ancillary mechanism for self-tolerance? Cell Immunol 2006; 244: 148-153.
7. De Groot AS. Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov Today 2006; 11: 203-209.
8. de Bruijn MH, Fey GH. Human complement C3: cDNA coding sequence and derived primary structure. Proc Natl Acad Sci USA 1985; 82: 708-712.
9. De Groot AS, Bosma A, Chinai N, Frost J, Jesdale BM, Gonzalez MA et al. From genome to vaccine: in silico predictions ex vivo verification. Vaccine 2001; 19: 4385-4395.
10. Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 2000; 18: 393-422.
11. Carroll MC. The complement system in B cell regulation. Mol Immunol 2001; 41: 141-146.
12. Luxembourg AT, Cooper NR. Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV. J Immunol 1994; 153: 4448-4457.
13. Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and selfantigens by the CD19/CD21 complex. Annu Rev Immunol 2000; 18: 393-422.
14. Mongini PK, Vilensky MA, Highet PF, Inman JK. The affinity threshold for human B cell activation is reduced upon co-ligation of the antigen receptor with CD21 (CR2). J Immunol 1997; 159: 3782-3791.
15. Kozono Y, Abe R, Kozono H, Kelly RG, Azuma T, Holers VM. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J Immunol 1998; 160: 1565-1572.
16. Cherukuri A, Cheng PC, Pierce SK. The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J Immunol 2001; 167: 163-172.
17. Wu CY, Kirman JR, Rotte MJ, Davey DF, Perfetto SP, Rhee EG et al. Distinct lineages of T(H)1 cells have different capacities for memory cell generation in vivo. Nat Immunol 2001; 3: 852-858.
18. Lambris JD, Ganu VS, Hirani S, Muller-Eberhard HJ. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc Natl Acad Sci USA 1985; 82: 4235-4239.
19. Bower JF, Ross TM. A minimum CR2 binding domain of C3d enhances immunity following vaccination. Adv Exp Med Biol 2006; 586: 249-264.
20. De Groot AS, Jesdale BM, Szu E, Schafer JR. An interactive web site providing MHC ligand predictions: application to HIV research. AIDS Res Hum Retroviruses 1997; 13: 539-541.
21. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998; 160: 3363-3373.
22. Roberts CG, Meister GE, Jesdale BM, Lieberman J, Berzofsky JA, De Groot AS. Prediction of HIV peptide epitopes by a novel algorithm. AIDS Res Hum Retroviruses 1996; 12: 593-610.
23. De Groot AS, Sbai H, Jesdale B, Martin W, Saint-Aubin C, Bosma A et al. Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach. Vaccine 2003; 21: 4486-4504.
24. Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera DS et al. Clinical validation of the 'in-silico' prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 2007; 124: 26-32.
25. Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 2006; 203: 961-971.